BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9794409)

  • 1. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II.
    Naujokas MF; Southwood S; Mathies SJ; Appella E; Sette A; Miller J
    Cell Immunol; 1998 Aug; 188(1):49-54. PubMed ID: 9743557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
    Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
    Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody.
    Eastman S; Deftos M; DeRoos PC; Hsu DH; Teyton L; Braunstein NS; Hackett CJ; Rudensky A
    Eur J Immunol; 1996 Feb; 26(2):385-93. PubMed ID: 8617308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
    Xu M; Jackson R; Adams S; Humphreys RE
    Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody detection of a major self peptide. MHC class II complex.
    Murphy DB; Rath S; Pizzo E; Rudensky AY; George A; Larson JK; Janeway CA
    J Immunol; 1992 Jun; 148(11):3483-91. PubMed ID: 1375245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
    Yaneva R; Springer S; Zacharias M
    Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular transport of MHC class II and associated invariant chain in antigen presenting cells from AP-3-deficient mocha mice.
    Sevilla LM; Richter SS; Miller J
    Cell Immunol; 2001 Jun; 210(2):143-53. PubMed ID: 11520080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC II and the endocytic pathway: regulation by invariant chain.
    Landsverk OJ; Bakke O; Gregers TF
    Scand J Immunol; 2009 Sep; 70(3):184-93. PubMed ID: 19703008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the dissociation and reassociation of MHC class II-foreign peptide complexes. Evidence that brief transit through an acidic compartment is not sufficient for binding site regeneration.
    Lee JM; Watts TH
    J Immunol; 1990 Mar; 144(5):1829-34. PubMed ID: 2307843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.